| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8283952 | Maturitas | 2018 | 7 Pages |
Abstract
This proof-of-principle study demonstrates that reverse engineering of TNBC cells might offer a novel targeted treatment strategy for this most aggressive subtype of breast cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Lena Bluemel, Marie-Kristin von Wahlde, Joke Tio, Ludwig Kiesel, Christof Bernemann,